Drug Profile
M 7583 companion diagnostic - HTG Molecular Diagnostics/Merck
Latest Information Update: 01 Jan 2021
Price :
$50
*
At a glance
- Originator HTG Molecular Diagnostics; Merck KGaA
- Developer HTG Molecular Diagnostics
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma
Most Recent Events
- 30 Dec 2020 HTG Molecular Diagnostics has patent protection for nuclease protection methods for detection of nucleotide variants in Canada
- 28 Nov 2020 No recent reports of development identified for research development in B-cell lymphoma(Diagnosis) in USA
- 03 Apr 2018 HTG Molecular Diagnostics has patent protection for nuclease protection methods for detection of nucleotide variants in Japan